Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS107 + toripalimab + oxaliplatin + capecitabine
- Development stage
- Phase 3
- Lead developer
- Junshi Biosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
JS107 + toripalimab + oxaliplatin + capecitabine is a combination therapy regimen being evaluated for the first-line treatment of CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The regimen consists of JS107, a claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate (ADC) carrying a monomethyl auristatin E (MMAE) payload; toripalimab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; and the XELOX chemotherapy backbone, which includes oxaliplatin and capecitabine. This combination aims to leverage the targeted cytotoxicity of the ADC, the immune checkpoint inhibition of toripalimab, and the systemic effects of chemotherapy to improve outcomes in patients with high CLDN18.2 expression. Clinical data has shown promising efficacy with high objective response rates in this patient population.
- Other names
- JS107 + toripalimab + oxaliplatin + capecitabine
02
Targets
DNAClaudin 18.2PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on JS107 + toripalimab + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS107 + toripalimab + oxaliplatin + capecitabine.